Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01286272
Title Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

follicular lymphoma

Therapies

Bendamustine + Ofatumumab

Bendamustine + Bortezomib + Ofatumumab

Age Groups: adult
Covered Countries USA


No variant requirements are available.